Announcement PDF 27 August 2026 Manager, Company Announcements ASX Limited Level 27 39 Martin Place SYDNEY NSW 2000 Via E-Lodgement Dear Sir/Madam Mayne Pharma Group Limited Full Year Results – financial year ended 30 June 2026 Please find attached the following documents relating to the results for the year ended 30 June 2026: • Appendix 4E • Annual Report This announcement comprises the information required by ASX Listing Rule 4.3A. Yours faithfully, Mayne Pharma Group Limited Laura Loftus Company Secretary Please click here to visit view the announcement Investor Hub. RESULTS FOR ANNOUNCEMENT TO THE MARKET APPENDIX 4E – PRELIMINARY FINAL REPORT % CHANGE 30 JUNE 2026 $’000 30 JUNE 2025 $’000 Revenue from ordinary activities (6) 383,676 408,095 Profit / (loss) from continuing operations before income tax expense 35,759 (83,296) Profit / (loss) from continuing operations after income tax expense 31,198 (90,071) Profit / (loss) from discontinued operations after income tax expense (6,725) (3,765) Profit / (loss) after income tax 24,473 (93,836) Attributable to: Equity holders of the parent Non-controlling interests 24,473 (93,836) - 24,473 (93,836) Other comprehensive profit/(loss) after income tax expense (8,396) 5,800 Total comprehensive profit/(loss) for the period 16,077 (88,036) Attributable to: Equity holders of the parent Non-controlling interests 16,077 (88,036) - 16,077 (88,036) 2026 $ 2025 $ Net tangible assets per ordinary share (1) ($0.90) ($2.22) Basic earnings per share $0.31 (1.19) Diluted earnings per share $0.21 (1.19) Final dividend in respect of the financial year ended 30 June per share Nil Nil Refer to the Review of Operations and Likely Developments and the accompanying ASX announcement dated 27 August 2026 for a brief commentary on the results. 1. Includes right-of-use lease assets. Annual Report 2026 Improving patient access to life‑enhancing medications What’s inside What we do 01 FY26 business highlights 02 Letter from the Chair and CEO 04 Directors’ Report 10 Remuneration Report 22 Auditor’s Independence Declaration 32 Corporate Governance Website 33 Consolidated Statement of Profit and Loss and other Comprehensive Income 34 Consolidated Statement of Financial Position 35 Consolidated Statement of Cash Flows 36 Consolidated Statement of Changes in Equity 37 Notes to the Consolidated Financial Statements 38 Consolidated Entity Disclosure Statement 73 Directors’ Declaration 74 Independent Auditor’s Report 75 ASX Additional Information 80 Intellectual Property & Glossary 81 Corporate Information iii At Mayne Pharma we are focused on keeping our promises to patients, for better medicines and a better tomorrow. We believe that everyone deserves medicines that are better, safe and more accessible. That’s why our people are determined to create innovative products and services for our changing world. Learn more at maynepharma.com Mayne Pharma Annual Report 2026 ii What we do Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. Mayne Pharma Annual Report 2026 1 FY26 business highlights Mayne Pharma at a glance $383.7m down 6% on FY25 64.7% FY26 gross margin, up from 60.6% in FY25 83% of group revenue from established brands, 17% generics $107.1m in direct contribution from business segments, down 2% versus FY25 $34.5m in adjusted operating cash flow from continuing operations down $10.9 million on FY25 $31.2m reported net profit after tax, versus a $90.1m net loss in FY25 >450 employees globally $248.2m gross profit, flat versus FY25 $34.2m in underlying EBITDA down 27% on FY25 5,042 unique prescribers joining DistributeRx platform since March 2026 launch $14.4m legal costs and interest recouped from Cosette Pharmaceuticals $80.0m cash and marketable securities at 30 June 2026 For further information visit the Group’s website at maynepharma.com Mayne Pharma Annual Report 2026 2 The 2026 financial year was a challenging year in which the Cosette transaction process and subsequent legal matters placed considerable demands on management focus and organisational bandwidth, including general disruption to our business. Against that backdrop, along with a planned leadership transition, our team delivered disciplined commercial execution, continued margin expansion and a landmark strategic initiative in the launch of DistributeRx. Mayne Pharma Annual Report 2026 3 Letter from the Chair & CEO Financial Performance FY26 Mayne Pharma generated $383.7 million in group revenue for FY26, with gross profit of $248.2 million and gross margin of 65%. Full year underlying EBITDA was $34.2 million, after absorbing increased investment in Women’s Health sales and marketing in 2H FY26 and higher post-market approval study costs in the Women’s Health portfolio. Several other structural drivers to the decline in EBITDA relative to FY25 were unfavourable foreign exchange movements, payments of short term incentives in FY26 compared to none being paid in FY25 and a managed care provider benefit being recognised in FY25. Across FY26, Mayne Pharma experienced general disruption and constraints in its business and operations as a result of the events around the Cosette transaction. Total direct segment contribution was $107.1 million in FY26, down 2% on the prior corresponding period (pcp), underpinned by strong Dermatology contribution growth of 11%. Operating expenses continued to reflect investment in promotional activities for Women’s Health, post approval studies for ANNOVERA® and IMVEXXY®, and the Cosette-related transaction and litigation costs, which are non-recurring in nature. Cash and marketable securities stood at $80.0 million at 30 June 2026. With three consecutive years of gross margin expansion and a strengthening cash position, Mayne Pharma enters FY27 with greater commercial momentum and a clearer pathway to sustained profitability. Dear Fellow Shareholders, The 2026 financial year (FY26) was a challenging year in which the Cosette transaction process and subsequent legal matters placed considerable demands on management focus and organisational bandwidth, including general disruption to our business. Against that backdrop, along with a planned leadership transition, our team delivered disciplined commercial execution, continued margin expansion and a landmark strategic initiative in the launch of DistributeRx. With three consecutive years of gross margin expansion and a strengthening cash position, Mayne Pharma enters FY27 with greater commercial momentum and a clearer pathway to sustained profitability. Mayne Pharma Annual Report 2026 4 The key highlights of FY26 were: • Underlying EBITDA: Underlying EBITDA was $34.2 million, primarily reflecting Cosette-related disruption and increased Women’s Health investment consistent with a strong outlook for the product portfolio. • Continued gross margin expansion: Group gross margin expanded to 64.7% in FY26, building on the 60.6% reported in FY25, reflecting a richer product mix, channel discipline and the growing contribution of branded products, which now represent 83% of net sales (up from 79% in FY25). • DistributeRx launch: In March 2026, Mayne Pharma launched DistributeRx — a transformational US direct- to-patient prescription distribution platform. Prescription demand exceeded our expectations in its first month of operation, validating our disintermediation strategy built over several years. • Women’s Health portfolio momentum: NEXTSTELLIS® demand cycles grew 15% in FY26, with strong double-digit growth across BIJUVA® (up 26% on the pcp) and continued growth in IMVEXXY® (up 6% on the pcp). The FDA’s removal of the Black Box warning for hormone replacement therapies represents a material positive macro tailwind for our menopause franchise. • Dermatology direct contribution surge: Dermatology direct contribution grew 11% in FY26 reflecting a shift in the dermatology product mix driving margin and contribution growth. Branded products increased as a share of the portfolio from 54% in FY25 to 58% in FY26, including from RHOFADE® and the successful launch of TWYNEO® and EPSOLAY®. • International transition: International segment revenue declined in FY26, driven by a transition from lower margin to higher margin products in the portfolio which has had a short term impact on performance, and additional investment into sales and marketing initiatives for NEXTSTELLIS® in Australia. NEXTSTELLIS® PBS listing (effective 1 October 2025) and expansion of KADIAN® supply in Canada were key positive contributors to the International result. The inauguration of the Salisbury facility in December 2025, following an $18 million capital investment, delivers a modernised manufacturing platform for sustainable export growth. • Cash position: Adjusted operating cash flows from continuing operations were down 24% in FY26, with cash and marketable securities of $80.0 million at 30 June 2026, providing balance sheet flexibility to reinvest into growth initiatives for the Company. • Leadership renewal: Professor Bruce Robinson was appointed Chair in January 2026, bringing deep clinical, scientific and governance expertise to the role. Aaron Gray was appointed Chief Executive Officer in February 2026, having served as CFO and playing a central role in delivering Mayne Pharma’s financial turnaround over the past two years. Mayne Pharma Annual Report 2026 5 Operational Achievements Women’s Health Our Women’s Health segment continued to build commercial momentum throughout FY26. NEXTSTELLIS®, which is the only oral contraceptive in the US containing estetrol, with Orange Book patent protection to 2043, delivered demand cycle growth of 15% in FY26, with US net sales of US$45.2 million (up 6% on the pcp). BIJUVA® delivered particularly strong performance, with total prescription (TRx) growth of 26% in FY26, reflecting removal of the FDA black box warning, targeted prescriber engagement and the effectiveness of our refreshed marketing materials launched across the portfolio in FY26. IMVEXXY® TRx grew 6% in FY26, also benefiting from the momentum in menopause and ANNOVERA® delivered steady volumes with expanded prescriber reach. The macro environment for our menopause franchise is improving materially. The FDA’s removal of the Black Box warning from hormone replacement therapies is a significant positive development for Women’s Health broadly and one from which Mayne Pharma is uniquely positioned to benefit given the quality and IP strength of our menopause portfolio. This warning was removed from BIJUVA® in February 2026. Gross margin for the Women’s Health segment was 79% in FY26, underpinning the premium nature of this franchise. Dermatology In Dermatology, FY26 was a pivotal year for both portfolio enrichment and the continued evolution of our disintermediation strategy. We launched TWYNEO® (tretinoin and ivermectin cream for acne) and EPSOLAY® (benzoyl peroxide cream for rosacea) in the US during 1H FY26, adding two differentiated, FDA-approved branded products to a franchise that has been strategically reshaped over the past two years. Dermatology gross margin reached 64% in FY26, up 10 percentage points on the pcp, reflecting the positive mix impact of new brand launches and the structural improvement in gross-to-net profiles achieved through channel optimisation. Direct contribution from Dermatology grew 15% in FY26, which demonstrates that the channel strategy is delivering tangible financial returns. Adelaide Apothecary, our specialist mail-order pharmacy, grew direct-to-patient revenues significantly in FY26. The channel ecosystem encompassing over 400 specialty pharmacies, Adelaide Apothecary and GoodRx-enabled prescribing access is now a genuine strategic asset and the foundation for the next phase of our disintermediation ambitions through DistributeRx. Letter from the Chair & CEO continued DistributeRx — A New Growth Platform The launch of DistributeRx in March 2026 marks a defining strategic milestone for Mayne Pharma. DistributeRx is a US- focused healthcare solutions business that creates a direct- to-patient prescription distribution channel, simplifying the pathway from prescription to patient through digital workflows, transparent cash-pay pricing and fulfilment via Adelaide Apothecary. By reducing reliance on traditional intermediaries, pharmacy benefit managers, wholesalers and large retail chains, DistributeRx improves patient affordability and access while substantially improving product economics for Mayne Pharma. The platform also provides manufacturer services including co-pay program optimisation, enhanced fulfilment solutions and direct-to-pharmacy contracting, opening a B2B revenue stream for third-party pharmaceutical clients. Early commercial results have exceeded expectations. Prescription demand through DistributeRx was ahead of internal forecasts in its first month of operation, with volumes continuing to build as new prescribers onboard. Daniel Moore, formerly General Manager of Mayne Pharma’s Dermatology business, has transitioned to President of DistributeRx, bringing over 20 years of healthcare commercial experience to the role. DistributeRx is positioned as a scalable ecosystem that can extend into adjacent therapeutic areas beyond Women’s Health and Dermatology. The platform taps into the rapidly expanding US digital pharmacy and direct-to-patient market, which represents a structural shift in how Americans access prescription medicines and builds on the infrastructure Mayne Pharma has developed over several years. Our objective is for DistributeRx to be a meaningful value driver for shareholders over the medium term. During FY26 we also moved to scale the platform’s infrastructure and reach. In May 2026, Mayne Pharma announced that Adelaide Apothecary will relocate and expand its US fulfilment operations into a new, automated facility in Lexington, Kentucky. This new facility is approximately four times Adelaide Apothecary’s current footprint and will increase annual capacity over two phases to more than 2.5 million prescriptions (an approximate seven-fold increase) to support the next phase of DistributeRx growth. Operations are expected to commence in early 2027. In June 2026, DistributeRx secured its first third-party manufacturer partnership, an exclusive US distribution agreement with Resilia Pharmaceuticals for RECEDO® topical silicone gel for scar management; the first product onboarded from outside Mayne Pharma’s own portfolio and early validation of the platform’s manufacturer-services model. Mayne Pharma Annual Report 2026 6 The launch of DistributeRx in March 2026 marks a defining strategic milestone for Mayne Pharma. DistributeRx is a US-focused healthcare solutions business that creates a direct-to-patient prescription distribution channel, simplifying the pathway from prescription to patient through digital workflows, transparent cash-pay pricing and fulfilment via Adelaide Apothecary. Mayne Pharma Annual Report 2026 7 Letter from the Chair & CEO continued International The$18millionSalisburyfacilityupgradewasformallyinaugurated inDecember2025,withthemodernisedplantreceivingrecognition acrossnationalandstateexportandbusinessawards.The completionofthisinvestmentdeliversenhancedmanufacturing capability,capacityfornewproductlaunchesandastepchangein operationalreliability—withon-time,in-fulldeliveryratesreaching 97.4%asat30June2026. NEXTSTELLIS®achievedalandmarkmilestoneinAustralia,withPBS listingeffective1October2025,broadeningpatientaccesstothis novelestrogen-containingcontraceptive.NEXTSTELLIS®achieved strongyear-on-yearprescriptiongrowthinAustralia,demonstrating thevalueofaccess-enablingmilestonesforcommercially matureproducts. Internationalsegmentrevenuedeclined7%inFY26,drivenby atransitionfromlowermargintohighermarginproductsinthe portfoliowhichhashadashorttermimpactonperformance,along withadditionalinvestmentintosalesandmarketinginitiativesfor NEXTSTELLIS®inAustralia.NEXTSTELLIS®PBSlistingandexpansion ofKADIAN®supplyinCanadawerekeypositivecontributorstothe Internationalresult.Wecontinuetopursuecontractdevelopment andmanufacturingopportunitiesthroughtheSalisburyfacilityto drivecapacityutilisationandmarginimprovement. Corporate Matters — Cosette Transaction In February 2025, the Board unanimously recommended a Scheme of Arrangement with Cosette Pharmaceuticals, Inc. at A$7.40 per share, representing a premium of approximately 50% to the 90-day VWAP of Mayne Pharma’s share price at announcement. At the Scheme Meeting in June 2025, shareholders voted overwhelmingly in favour of the Scheme, with 99.06% of votes cast in support. However, Cosette subsequently failed to satisfy its obligations under the Scheme Implementation Deed, and the matter proceeded to litigation in the Supreme Court of New South Wales. In October 2025, the Court found that Cosette had not validly terminated the Scheme Implementation Deed, vindicating the Company’s position, and subsequently awarded costs in Mayne Pharma’s favour. On 5 June 2026, the Company received $14.4 million from Cosette in full satisfaction of those court-ordered legal costs and interest. Cosette has appealed the October 2025 judgment and that appeal was heard by the New South Wales Court of Appeal on 2 and 3 June 2026, with the Court reserving its decision. Separately, in February 2026 Mayne Pharma commenced proceedings seeking substantial damages from Cosette and associated parties for breach of, and inducing breach of, the Scheme Implementation Deed, and those proceedings continue. The Board and management team maintained focus throughout this period on operational execution. Board and Leadership Renewal FY26 brought meaningful renewal at both board and management level. Mr Frank Condella retired as Non-Executive Director and Chair with effect from 14 January 2026, following almost eight years of dedicated service including over four years as Chair. On behalf of the Board and all shareholders, we thank Frank for his leadership and the considerable value he contributed to Mayne Pharma through significant business transformation. Professor Bruce Robinson was appointed Chair in January 2026, bringing extensive clinical, scientific and governance credentials including his role as a Non-Executive Director of Cochlear Limited and former Dean of the University of Sydney Medical School. Mr Patrick Blake and Mrs Anne Lockwood stepped down as Non-Executive Directors following the release of 1H FY26 results in February 2026, and Dr Katie MacFarlane stepped down at the end of May 2026. The Board thanks Pat, Anne and Katie for their contributions. At the management level, Mr Shawn Patrick O’Brien stepped down as Managing Director and Chief Executive Officer on 20 February 2026, in a planned and orderly transition. Shawn led the business through a defining period of transformation — from a complex multi-segment business to a focused specialty pharmaceutical company with a clear Women’s Health and Dermatology identity — and we thank him for his commitment and leadership. Mr Aaron Gray was appointed Chief Executive Officer in February 2026 with immediate effect. Aaron joined Mayne Pharma as Chief Financial Officer in 2022 and has been central to the financial and strategic transformation of the Company, including the Cosette transaction process, the margin expansion program and the development of DistributeRx. In July 2026, the Company announced the appointment of Mr Griffin D. Buchanan as Chief Financial Officer from 1 August 2026. Mr Buchanan is a senior finance executive with extensive experience in global medical technology and healthcare who understands the global medical technology and women’s health markets first-hand. Mayne Pharma Annual Report 2026 8 In June 2026, the Board further strengthened its composition with the appointment of Ms Meghan Rivera as a Non-Executive Director. Ms Rivera has more than 25 years’ experience in the US pharmaceutical industry across multiple therapeutic areas including women’s health. Ms Rivera currently serves as Vice President and Global Commercial Lead for ViiV Healthcare, a leading biopharmaceutical organisation focussed on the prevention, treatment and cure of HIV. Her prior roles include US Market President at Organon & Co (NYSE: OGN), Chief Marketing Officer and Head of Commercial at Akili Interactive and Senior Vice President of Women’s Health at AMAG Pharmaceuticals. Ms Rivera’s appointment adds deep US commercial and Women’s Health expertise to the Board as Mayne Pharma scales its branded franchises and the DistributeRx platform. On 14 August 2026, Mr Jacob Ma-Weaver joined the Board. Mr Ma-Weaver, a US resident, is the Managing Member of Cable Car Capital, LP (Cable Car), an investment adviser he founded in 2013. Cable Car is the General Partner of Funicular Funds, LP, a hedge fund which holds 9.90% of the fully paid ordinary shares in the Company. Mr Ma-Weaver was an investment analyst at Amici Capital LLC, where he focused on healthcare. He previously worked as an equity research associate at Dodge & Cox and a corporate finance business analyst at McKinsey & Company. Jacob brings extensive experience as an investor and analyst in the life sciences and healthcare industries. Outlook Mayne Pharma enters FY27 with operational momentum, a strong balance sheet and a clear strategic agenda. In Women’s Health, the priority is to accelerate portfolio growth through a focused salesforce, refreshed marketing and improved prescriber access, underpinned by the macro tailwind from the removal of the HRT Black Box warning of the menopause category, in particular for BIJUVA®. In Dermatology, we will continue to extend the disintermediation model while expecting some loss of insurance coverage for TWYNEO® during the year and generic entry into the RHOFADE® market. The DistributeRx platform will be a significant area of focus. With prescription volumes already materially exceeding our internal forecasts, we see an opportunity to scale this platform across additional products and therapeutic areas while leveraging Mayne Pharma’s established infrastructure. Internationally, we will build on NEXTSTELLIS® growth following the PBS listing in Australia, and leverage the Salisbury investment to deliver export growth and contract manufacturing revenues. We will also continue to evaluate capital-efficient, synergistic acquisitions that can leverage our existing Women’s Health and Dermatology ecosystems, alongside disciplined capital management. On behalf of the Board, we wish to express our sincere thanks to all Mayne Pharma employees for their dedication and commitment during what was a challenging year of external uncertainty. Their focus on operational execution and patient outcomes has been the foundation of the commercial progress we are reporting. We also thank our shareholders for their continued support and for their patience through the Cosette transaction process. We are encouraged by the underlying strength of this business with solid gross margins, an expanding branded portfolio, strengthening cash generation and a genuinely innovative new platform in DistributeRx. We look forward to demonstrating continued progress. Thank you for your continued support. Professor Bruce Robinson Chair Aaron Gray Chief Executive Officer Mayne Pharma Annual Report 2026 9 Mayne Pharma Annual Report 2026 10 Directors’ Report Mayne Pharma Group Limited Financial Statements for the year ended 30 June 2026 2 DIRECTORS’ REPORT The Directors of Mayne Pharma Group Limited (‘the Company’) present their report together with the financial report of the Company and its controlled entities (collectively the ‘Group’ or ‘Consolidated Entity’ or ‘Mayne Pharma’) for the year ended 30 June 2026 and the Auditor’s Report thereon. The information set out below is to be read in conjunction with the Remuneration Report set out on pages 22 to 31, which forms part of this Directors’ Report. DIRECTORS The Directors of the Company during the financial year and up to the date of this report are set out below. Directors were in office for this entire period unless otherwise noted. Prof Bruce Robinson, AC, Chair (Chair effective from 14 January 2026) Ms Ann Custin Mr David Petrie Ms Meghan Rivera (appointed 26 June 2026) Mr Jacob Ma-Weaver (appointed 14 August 2026) Mr Frank Condella (retired from the Board and Chair role effective 14 January 2026) Mr Shawn Patrick O’Brien (stepped down as CEO and Managing Director effective 20 February 2026 US time) Mr Patrick Blake (resigned 28 February 2026) Mrs Anne Lockwood (resigned 28 February 2026) Dr Kathryn MacFarlane (resigned 31 May 2026) The Directors’ qualifications, other listed company directorships, experience and special responsibilities are detailed on pages 19 of this report. The qualifications and experience of the Company Secretary are detailed on page 19 of this report. DIRECTORS’ MEETINGS The number of Directors’ meetings (including meetings of committees of Directors) and number of meetings attended by each of the Directors of the Company during the 2026 financial year are: BOARD AUDIT & RISK COMMITTEE NOMINATION COMMITTEE REMUNERATION & PEOPLE COMMITTEE SCIENCE, TECHNOLOGY & MEDICAL COMMITTEE HELD1 ATTENDED2 HELD1 ATTENDED2 HELD1 ATTENDED2 HELD1 ATTENDED2 HELD1 ATTENDED2 Prof B Robinson 32 28 1 1 1 1 1 1 2 2 Ms A Custin4 32 32 6 6 1 1 5 6 - - Mr D Petrie 32 32 6 6 1 1 9 9 - 1 Ms M Rivera 1 1 - - - - - - - Mr F Condella3 22 22 - 2 4 4 - - Mr S O’Brien3,4 25 25 - 5 - 5 - - Mr P Blake 25 22 5 4 6 6 - - Mrs A Lockwood 25 22 5 5 - - - - Dr K MacFarlane 31 31 - - 1 1 3 2 2 2 1. This column shows the number of meetings held during the period the Director was a member of the Board or Committee. 2. This column shows the number of meetings attended. 3. Mr O’Brien and Mr Condella are not members of the Audit and Risk Committee however they attend meetings at the Chair’s invitation. 4. Mr O’Brien was not a member of the Remuneration and People Committee however he attended meetings at the Chair’s invitation. 5. Ms Custin was not a member of the Remuneration and People Committee until January 2026, however she attended meetings at the Chair’s invitation. 6. Mr Petrie is not a member of the Science, Technology and Medical Committee, however he attends meetings at the Chair’s invitation. SIGNIFICANT CHANGES IN THE STATE OF AFFAIRS The Group continues to develop and invest in existing assets as well as expand its disintermediation strategy to enhance growth opportunities. This included the launch of DistributeRx in March 2026 and the new automated facility to deliver a seven-fold increase in capacity over two phases. Work on the Salisbury modernisation project, partly funded by a federal government grant, was completed during the period. Official inauguration of the upgrade occurred in December 2025. Pharmaceutical Benefits Scheme (PBS) approval for NEXTSTELLIS® in Australia was received in September 2025. TWYNEO® and EPSOLAY® were launched in the United States during the year. Cosette litigation As announced on 5 June 2026 Mayne Pharma received a total of $14.4 million from Cosette, comprising recovery of the Company’s legal costs of the proceedings, the costs associated with its application for costs, and interest. In January 2026, Cosette appealed the Court’s October 2025 judgment. The appeal was heard by the Supreme Court of New South Wales, Court of Appeal on 2 and 3 June 2026 and the decision has been reserved. On 18 February 2026, Mayne Pharma commenced proceedings in the Supreme Court of New South Wales against Cosette Pharmaceuticals, Inc, Cosette Pharmaceuticals Holdings, Inc, Avista Capital Holdings, LP trading as Avista Healthcare Partners (Avista) and David Burgstahler (the Managing Partner and CEO of Avista) seeking substantial damages on behalf of Mayne Pharma shareholders against Cosette for breach of the Scheme Implementation Deed (SID) and against the other defendants for inducing Cosette’s breach of the SID. Mayne Pharma is also seeking substantial damages on its own behalf against the defendants. Mayne Pharma Annual Report 2026 11 Mayne Pharma Group Limited Financial Statements for the year ended 30 June 2026 3 PRINCIPAL ACTIVITIES Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising branded women’s health and dermatology pharmaceuticals. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that continue to be marketed around the world. Mayne Pharma has a product development and manufacturing facility based in Salisbury, Australia with expertise in the formulation of complex oral and topical dose forms including modified-release products and poorly soluble compounds. REVIEW OF OPERATIONS AND LIKELY DEVELOPMENTS Summary of financial performance Set out below is a summary of the financial performance attributable to Mayne Pharma shareholders for the 2026 financial year (FY26) compared to the prior corresponding period (pcp). This summary includes non-IFRS Accounting financial information that is stated excluding certain non-operating income and expense items. The results are set out this way as the Directors consider them to be a meaningful comparison from period to period that are useful for the users of this financial report as they provide additional and relevant information that reflect the underlying performance of the business. Key measures of earnings considered by management in operating the business and assessing performanc